The company's patented drug, MANF, already has four orphan indications and one orphan designation as a potential treatment for Retinitis Pigmentosa.
It appears you're back on board. Ready for another run at .20?
If you invest in bio-tech you should consider Amarantus Bioscience -AMBS - currently under a dime.
The company recently launched its diagnostic test, LymPro, that detects early stage Alzheimer's. Potential $3B annual market.
The company also has several orphan indications for its patented drug MANF.
Read yesterday's Yahoo news for AMBS.